FDA Restrictions on Psychedelic Research

FDA restrictions on psychedelic research transformed a methodological dispute into an institutional rupture. They limited the conditions under which researchers could study LSD and psilocybin, helped drive investigators outside the university system, and eventually closed nearly every psychedelic research program then operating in the United States. Their legacy is not simply a history of prohibition: the same questions that made these therapies difficult to regulate—how to measure an experience, control its context, and separate drug effects from therapeutic care—remain central to their evaluation.

From therapeutic promise to regulatory scrutiny

By the end of the 1950s, LSD had become widely regarded in North America as a promising treatment for alcohol addiction. In Saskatchewan, the provincial government helped make LSD therapy a standard treatment option. The results were disputed, however. In the early 1960s, Toronto’s Addiction Research Foundation attempted a more controlled replication, placing volunteers in neutral rooms, limiting interaction with clinicians, and administering extensive questionnaires. Some participants were constrained or blindfolded. The results did not match those reported in Saskatchewan, and several volunteers had frightening experiences. Critics took the findings as evidence that the treatment failed under rigorous controls; its supporters argued that the controlled conditions had removed the attentive therapeutic setting on which the treatment depended.

The conflict over research design coincided with a change in federal authority. After the thalidomide tragedy, in which a drug given to pregnant women caused severe birth defects in their children, Congress gave the FDA authority to regulate experimental drugs. At Harvard, new restrictions placed the university’s supply of psilocybin under Health Services’ control. By the end of the year, Timothy Leary and Richard Alpert concluded that the substances were too controversial to study in a university setting. They announced the International Federation for Internal Freedom as a new organizational umbrella for their research and described the emerging situation as a scientific underground. Their appeal framed the restrictions not only as a question of drug oversight but also as a dispute over who could investigate consciousness.

A mismatch between psychedelic therapy and the trial model

Psychedelic therapy challenged established psychiatric categories as well as regulatory practice. Earlier models could treat the drugs as producing effects resembling psychosis, or as aids to psychoanalysis. The newer therapeutic approach instead relied on a high-dose session intended to occasion a major psychological change, requiring a different conception of the roles of patient and therapist. Its spiritual dimensions also blurred distinctions between medical treatment and religious experience, sickness and health, and clinician and sufferer.

These features sat uneasily with the growing authority of the double-blind, placebo-controlled trial, elevated after the thalidomide scandal as the standard for drug testing. Psychedelic trials are difficult to blind because participants and guides can often tell whether the active drug was administered. Nor is it straightforward to isolate the drug from the volunteer’s expectations, the therapist’s involvement, or the setting. The Saskatchewan-Toronto contrast made that tension concrete: procedures intended to control outside variables could also change the experience being studied. For regulators and researchers alike, the question was how to assess a treatment in which context might be part of the method rather than a removable source of error.

The 1966 shutdown and a narrow exception

In May 1966, Timothy Leary and Sidney Cohen testified at Senate hearings on LSD, defending legitimate research while distinguishing it from black-market use. Their arguments did not prevent the next step. In October, the FDA sent letters to about sixty psychedelic researchers across the United States ordering them to stop their work.

The order reached the International Foundation for Advanced Study in Menlo Park at a moment that made the interruption unusually stark. James Fadiman had just finished administering psychedelics to four participants in a creativity and problem-solving experiment when the revocation letter arrived. He and his colleagues delayed acting on it until the following day; then the foundation’s program, along with virtually every other U.S. research program of the period, closed.

The Maryland Psychiatric Research Center at Spring Grove was the major exception. Researchers there, including Stanislav Grof, Bill Richards, Richard Yensen, and Walter Pahnke, continued work with psilocybin and LSD on alcoholism, schizophrenia, and the existential distress of cancer patients. The program lasted until 1976. The reason it survived remains uncertain, but the center’s director, Albert Kurland, had strong connections in Washington and used them to keep the program running and obtain LSD, including some from the government. Its continuation preserved a limited line of research after the wider shutdown.

Continuing consequences for research

The closure interrupted a body of inquiry that later researchers would have to recover and test under contemporary standards. In the renewed research of the 2010s, the old design problem had not disappeared: investigators still faced the difficulty of blinding psychedelic trials and distinguishing pharmacological effects from the influence of expectations, therapists, and setting. The FDA’s role in regulating experimental drugs thus became part of a larger question about whether conventional methods could adequately assess a treatment delivered through a carefully shaped experience.

The 2016 publication of the New York University and Johns Hopkins cancer studies showed both the promise and the limits of the returning evidence. Across the two trials, about 80 percent of participants showed clinically significant reductions in anxiety and depression, sustained for at least six months; the reported intensity of mystical experience closely tracked symptom improvement. But the combined studies included only eighty subjects, and larger trials would be needed before the government could consider rescheduling psilocybin and approving the treatment. The results brought renewed attention and calls for further study, not definitive proof of a cure.

That distinction remains essential to the history of regulation. Early enthusiasm for psychedelic therapies has repeatedly risked outrunning the evidence, especially when small studies involve carefully selected participants and unusually attentive therapists. At the same time, a regulatory framework that demands the isolation of a single variable may struggle with therapies whose effects appear bound up with the circumstances of administration. The history of FDA restrictions therefore records an unresolved balance: the need for rigorous safety and evidence, and the challenge of evaluating a treatment whose therapeutic context may be inseparable from what it does.